In the global race to develop an effective vaccine to protect people against the novel coronavirus, China’s CanSino Bio has leapt ahead.
CanSino and its collaborators at the Academy of Military Medical Sciences’ Institute of Biotechnology plan to move their adenovirus Type 5 vector-based recombinant COVID-19 vaccine, Ad5-nCoV, into phase 2 clinical trial in China “soon,” the company said in a disclosure (PDF) to Hong Kong Stock Exchange on Thursday.
The company said the partnership made the decision “[b]ased on the preliminary safety data of the phase 1 clinical trial,” whose detailed results have not been shared.
In fact, virtual enrollment of the phase 2 study where interested individuals can sign up via a QR code has already started, putting CanSino ahead of all the others on a long list of COVID-19 vaccine developers.
It was only in mid-March when CanSino kicked off the first-in-human trial of Ad5-nCoV in healthy volunteers in the city of Wuhan, then the epicenter of the outbreak. Moving a vaccine from phase 1 into phase 2 in just three weeks is super-fast if not unprecedented even with all the urgency around an ongoing pandemic, making the process looks more like a phase 1/2 paradigm.
RELATED: Swelling ranks of COVID-19 vaccines in human testing, Inovio doses its first patients
Per the phase 1 trial design, 108 subjects are supposed to be followed for up to six months for analyses of safety as well as T-cell and antibody responses. The study’s primary endpoint was set to look at adverse reactions seven days post injection, data that CanSino likely already have.
According to the phase 2 protocol CanSino’s partner posted Friday on China’s clinical trial registry, the new study will again be conducted in Wuhan and will enroll 500 healthy participants. It’s worth noting that the investigators have abandoned the highest dose used in the phase 1 trial. This time, 250 people will get the middle dose, and the rest 250 will be split up to receive either the low dose or placebo.
The randomized study has three primary endpoints, which will examine adverse reactions within the first 14 days of vaccination, as well as serum levels of anti-SARS-CoV-2 neutralizing antibody and antibody against the coronavirus’ spike protein at day 28. Again, all participants will be followed for up to six months.
RELATED: Biopharma’s no-holds-barred fight to find a COVID-19 vaccine: The full list
Previously, Moderna, in partnership with the National Institutes of Health, was the first around the world to start testing a COVID-19 shot in humans. The Cambridge, Massachusetts-based biotech has an mRNA candidate, mRNA-1273. It contains genetic messages encoding for a stabilized form of the spike protein, which the coronavirus uses to infect host cells.
Moderna isn’t so far behind. In a recent interview with CNBC, Moderna Chairman Noubar Afeyan said the company’s hopeful it could enter phase 2 “in the spring, perhaps early summer.” In a securities filing, the company said that it might seek emergency use of the vaccine and make it available to some people, including healthcare professionals, possibly in the fall of 2020.
Vaccine is viewed a key step in the world’s transition from the current pandemic to business as usual. According to a road map compiled by experts including former FDA commissioners Scott Gottlieb and Mark McClellan, the current social distancing restrictions can only be lifted when safe and effective tools for mitigating the risk of the disease—including a vaccine—are available.
